Eisai Co., Ltd. (ESAIY) Discusses On Latest Data On Lemborexant And Novel Orexin Receptor Agonist E2086 At The World Sleep 2025 Transcript

Core Insights - The World Sleep 2025 conference took place in Singapore, where the Phase I study results of E2086 were presented [2] - Dr. Katsutoshi Ido, the Chief Scientific Officer, led the presentation and addressed audience questions to enhance understanding of E2086 [2] Group 1 - The presentation of E2086's Phase I study results was a highlight of the World Sleep 2025 event [2] - The session was conducted virtually, and additional presentation materials are available on the company's website [1]